InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for HealthGlobeNewsWire • 10/13/21
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPSGlobeNewsWire • 07/23/21
InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021GlobeNewsWire • 06/02/21
InspireMD to Participate at the Investor Summit Conference and Present to Investors on May 17, 2021GlobeNewsWire • 05/14/21
InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory BoardGlobeNewsWire • 04/29/21
InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company's Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of StockholdersGlobeNewsWire • 03/22/21
InspireMD, Inc.'s (NSPR) CEO Marvin Slosman on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/09/21
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate UpdateGlobeNewsWire • 03/02/21
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United StatesGlobeNewsWire • 02/24/21